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We recently identified a class of pimelic diphenyla-
mide histone deacetylase (HDAC) inhibitors that
show promise as therapeutics in the neurodegen-
erative diseases Friedreich’s ataxia (FRDA) and
Huntington’s disease. Here, we describe chemical
approaches to identify the HDAC enzyme target
of these inhibitors. Incubation of a trifunctional
activity-based probe with a panel of class I and class
II recombinant HDAC enzymes, followed by click
chemistry addition of a fluorescent dye and gel elec-
trophoresis, identifies HDAC3 as a unique high-
affinity target of the probe. Photoaffinity labeling in
a nuclear extract prepared fromhuman lymphoblasts
with the trifunctional probe, followed by biotin addi-
tion throughclick chemistry, streptavidin enrichment,
and Western blotting also identifies HDAC3 as the
preferred cellular target of the inhibitor. Additional
inhibitors with different HDAC specificity profiles
were synthesized, and results from transcription
experiments in FRDA cells point to a unique role for
HDAC3 in gene silencing in Friedreich’s ataxia.
INTRODUCTION
Histone deacetylase (HDAC) inhibitors have received consider-
able attention as potential therapeutics for cancer (Marks and
Breslow, 2007) and for a variety of neurological and neurodegen-
erative diseases (Kazantsev and Thompson, 2008). In this latter
context, we recently described a series of pimelic diphenylamide
HDAC inhibitors that reverse heterochromatin-mediated silenc-
ing of the frataxin (FXN) gene in the neurodegenerative disease
Friedreich’s ataxia (FRDA) (Herman et al., 2006) and also show
efficacy in a mouse model for Huntington’s disease (HD)
(Thomas et al., 2008). FRDA is caused by the expansion of
the simple triplet repeat DNA sequence GAAdTTC within intron 1
of the FXN gene, encoding the essential mitochondrial protein
frataxin. Repeats over a threshold level of 70 induce hetero-
chromatin formation (Herman et al., 2006) and concomitant
gene silencing, resulting in decreased amounts of frataxin
protein. Importantly for therapeutic development, the pimelic
diphenylamides cross the blood-brain barrier, cause global980 Chemistry & Biology 16, 980–989, September 25, 2009 ª2009increases in histone acetylation in cells and in the mouse brain,
and show good tolerance in murine models of disease (Rai
et al., 2008; Thomas et al., 2008). These molecules also directly
affect the histone acetylation status of FXN gene chromatin in
FRDA patient cells and in the mouse brain, increasing acetylation
at particular lysine residues on histones H3 and H4, and increase
FXN gene expression in the brain and heart in a mouse model for
FRDA (Rai et al., 2008). Strikingly, gene expression microarray
analysis indicates that most of the differentially expressed genes
in FRDA mice revert toward wild-type levels on treatment with
the pimelic diphenylamide HDAC inhibitor (Rai et al., 2008).
Similar results have been obtained in a mouse model for HD,
where one of these compounds ameliorated the disease pheno-
type and reversed many of the transcriptional abnormalities
found in the brain of R6/2 HD mice (Thomas et al., 2008).
Although the pimelic diphenylamides show considerable
promise for clinical development, we unexpectedly found that
only compounds related to the commercial product BML-210
are effective activators of the FXN gene in FRDA cells, and
none of the common HDAC inhibitors, such as valproic acid, tri-
chostatin A (TSA), and suberoylanilide hydroxamic acid (SAHA),
have a positive effect on FXN mRNA levels (at their reported IC50
concentrations). This result was surprising because many of
these common HDAC inhibitors are more potent inhibitors
than BML-210 and our derivatives when assayed in vitro or in
cell culture. These findings suggest that there is either a
unique cellular target for activation of FXN gene expression
that is not inhibited in the context of cellular chromatin by the
potent HDAC inhibitors, or some unusual mode of action of the
pimelic diphenylamides compared to the hydroxamic acids
SAHA and TSA. In a recent study, we reported that one of our
pimelic diphenylamides (compound 106; Figure 1) is specific
for class I histone deacetylases (comprising HDACs 1, 2, 3,
and 8), with no apparent inhibitory activity against class II
enzymes (Chou et al., 2008). We found that 106 exhibits a Ki of
14 nM for HDAC3, compared with 10–15-fold higher Ki values
for HDAC1 and HDAC2, and is only weakly active against
HDAC8. Inhibition of HDAC3 with 106 is through a slow, tight-
binding mechanism, and cells treated with this compound
show prolonged histone acetylation and frataxin protein expres-
sion, even after removal of the inhibitor (Chou et al., 2008). These
properties contrast with a rapid-on/rapid-off inhibition mecha-
nism observed for the hydroxamates SAHA and TSA, both
in vitro and in cell culture. We now report the identification of
HDAC3 as the preferred cellular target of the pimelicElsevier Ltd All rights reserved
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HDAC1 and inhibitors of class II and III HDACs fail to increase
FXN gene expression in FRDA lymphocytes, pointing to a
unique role of HDAC3 in FXN gene silencing in FRDA and sug-
gesting that this enzyme is a valid therapeutic target in this
disease.
RESULTS
Activity Profiling Approach for Target Identification
To provide evidence as to the cellular target(s) of our inhibitors,
and the possible role of these targets in gene silencing in
FRDA, we synthesized an activity-profiling probe for proteomic
studies (Evans and Cravatt, 2006; Hagenstein et al., 2003;
Hagenstein and Sewald, 2006). This approach has recently
been employed for the identification of the HDAC targets of
SAHA in cancer cells (Salisbury and Cravatt, 2007; Salisbury
and Cravatt, 2008), and HDACs 1 and 2 were identified, as would
be expected from previous studies of this compound (Marks
et al., 2001). Our trifunctional probe (1-BP; Figure 1) consists of
a benzophenone photolabeling group, which is attached through
a flexible ethylene glycol linker to HDAC inhibitor 106 (Rai et al.,
2008) and an alkyne for subsequent attachment of an azide-
linked reporter dye or biotin for affinity capture. Prior to using
1-BP for target identification, it was important to demonstrate
that this compound retained HDAC inhibitory activity and, hence,
was capable of binding HDAC enzymes. 1-BP had a lower IC50
value for HDAC inhibition using a HeLa cell nuclear extract as
a source of HDACs than did 106 (IC50 for 106 = 1.3 mM; IC50
for 1-BP = 0.3 mM; see Figure S1A and Table S1 available online),
whereas comparable IC50 values were obtained with recombi-
nant HDAC3/NcoR2 (IC50 for 106 = 0.79 mM; IC50 for 1-BP =
Figure 1. Structures of HDAC Inhibitors and
Activity-Profiling Probes
Inhibitors and probes are as follows: 106; the
trifunctional probe 1-BP and its control derivative
2-BP, lacking a 2-amino group; the HDAC1/2-
specific inhibitor 3 and the activity-profiling probe
3-BP; and the class II HDAC inhibitor 4.
0.86 mM; Figure S1C and Table S1). In
the case of recombinant HDAC1, a small
loss in activity was noted for 1-BP, com-
pared with 106 (IC50 for 106 = 0.24 mM;
IC50 for 1-BP = 0.57 mM; Figure S1B and
Table S1); however, 1-BP still inhibited
this enzyme at concentrations required
for target identification.
Having established that the probe
retains HDAC inhibitory activity, we next
used 1-BP for target identification. We
incubated 1-BP with identical amounts
of each of the recombinant class I
HDAC enzymes (HDACs 1, 2, 3, and 8)
and with two representative class II
enzymes (HDACs 4 and 5). Note that
each of these enzymes is catalytically
active (Chou et al., 2008 and data not
shown). After irradiation to effect photo-cross-linking, a fluores-
cent dye (rhodamine)-azide was attached to the probe by solu-
tion-phase Cu(I)-catalyzed click chemistry (Salisbury and Cra-
vatt, 2007). After SDS-PAGE, the gels were exposed to the
excitation wavelength of rhodamine, and fluorescent images
are presented in Figure 2A. These experiments clearly show
that, at least among these six enzymes, 1-BP exhibits a clear
preference for HDAC3. The probe is cross-linked to both
HDAC3 (49 kDa) and its cofactor NcoR2 (40 kDa fragment;
Yang et al., 2002). Low levels of cross-linking to recombinant
HDAC1 are observed at higher input concentrations of enzyme
(data not shown). To establish the specificity of the 1-BP/
HDAC3 cross-linking reaction, we performed a competition
experiment with the parent compound 106 (Figure 2B), where
the reactivity of 1-BP with HDAC3 is strongly competed by
preincubation with an equal concentration of 106 prior to the
addition of 1-BP. The intensity of the band corresponding to
NcoR2 was also diminished by preincubation with 106, but not
as significantly as HDAC3, suggesting that some reactivity with
NcoR2 may be nonspecific.
We previously reported that 106 exhibits a slow-on/slow-off
inhibition mechanism with HDAC3, likely involving a conforma-
tional change in the enzyme on binding the inhibitor, and kinetic
studies suggested that the half-life of the 106-HDAC3 complex
was on the order of 6 hr (Chou et al., 2008). To provide
a physical estimate of this half-life for the photoaffinity version
of 106, we performed a competition experiment where we first
incubated recombinant HDAC3/NcoR2 with 1-BP for 2 hr (in
the absence of UV irradiation) prior to the addition of a 20-fold
molar excess of 106. Samples were then taken at various times,
subjected to UV cross-linking and click chemistry addition of the
rhodamine-azide, as described above. We expect that, upon
Chemistry & Biology 16, 980–989, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 981
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Recombinant HDAC Enzymes
(A) Five micrograms of each of the indicated
recombinant HDAC enzymes were incubated
with 1-BP (at 4 mM) for 5 min, followed by UV irra-
diation for 1 hr; rhodamine azide was added by
click chemistry. A fluorescent image of an SDS-
PAGE is shown, and fluorescent dye markers are
shown at the left of the gel. Note that HDAC3
consists of the enzyme plus its required cofactor
NcoR2, which is a recombinant fragment that
is also cross-linked by 1-BP. Minor bands at
80 kDa and above represent multimers of
HDAC3/NcoR2. Reactions for the class I HDACs
1, 2, 3, and 8 were analyzed on a separate gel
from the reactions with the class II HDACs 4 and 5.
(B) Competition with 106. HDAC3/NcoR2 was
incubated with or without 106 at 10 mM, for 2 hr
at RT, prior to the addition of 1-BP (10 mM), fol-
lowed by photo-cross-linking and click chemistry
as in A.
(C) Determination of the half-life of the 1-BP/
HDAC3 complex. 1-BP and recombinant HDAC3/
NcoR2 were preincubated for 2 hr prior to the
addition of a 20-fold molar excess of 106, and
samples were withdrawn at the indicated times
and UV cross-linked; a rhodamine-azide was
added by click chemistry. The inset shows a fluo-
rescence image of an SDS-PAGE analysis of these
samples, and the graph is a plot of the natural log
of the fraction 1-BP/HDAC3 remaining at each
time point, relative to the zero time point, versus
time. ImageQuant software was used to quantify
the data, which were normalized for HDAC3
protein concentration in each sample (determined
by Western blotting, not shown). A least-squares
fit of the data (solid line, R2 = 0.934) yields a t1/2
of 4 hr.dissociation of 1-BP from HDAC3, the excess of 106 will largely
prevent reassociation of 1-BP with the enzyme, and the rate
of disappearance of the fluorescent signal can be used to deter-
mine the half-life of the 1-BP/HDAC3 complex. Figure 2C shows
that the intensity of the fluorescent band corresponding to the 1-
BP-HDAC3 complex disappears slowly, and quantification of
these data suggest a half-life of4 hr for this complex, in reason-
able agreement with our previous kinetic estimate for the half-life
of the 106-HDAC3 complex (Chou et al., 2008).
Cellular Target of the Activity Probe
We next sought to identify targets of 1-BP in nuclear extracts. We
prepared a nuclear extract from an Epstein Barr virus-trans-
formed lymphoid cell line derived from an FRDA patient (line
GM15850, alleles with 650 and 1030 GAA$TTC repeats in FXN,
from the NIGMS Human Genetic Cell Repository, Coriell Institute,
Camden, NJ). After incubation of 1-BP with the nuclear extract
and photo-cross-linking, a biotin tag was appended to the probe
through Cu(I)-mediated click chemistry (Salisbury and Cravatt,
2007). Streptavidin beads were then used for affinity capture of
probe-labeled protein targets, and Western blotting with anti-
bodies to the class I HDAC enzymes HDAC1, 2, and 3, was
used for target identification. Since the parent compound 106 is982 Chemistry & Biology 16, 980–989, September 25, 2009 ª2009only weakly active against recombinant HDAC8 (see above), we
did not pursue this enzyme further. Differences in band intensity
for the input lanes (lane 1 for each blot) could reflect differences in
either HDAC protein abundance or antibody avidity as equivalent
amounts of nuclear extract protein were used for each of the
blots shown in Figure 3A. In agreement with results for the
recombinant HDACs (Figure 2), HDAC3 is indeed cross-linked
by 1-BP and retained by the streptavidin beads using this
approach. In contrast, the other class I HDACs 1 and 2 failed to
react with the probe and were not retained by the streptavidin
beads, again in accord with results for the recombinant HDACs.
Quantification of these data reveal that as much as 2%–4% of
the input HDAC3 protein is retained by the streptavidin beads in
this experiment. Importantly, preincubation of the nuclear extract
with the parent compound 106 significantly reduces the HDAC3
signal in this experiment (Figure 3A, lane 3), demonstrating the
specificity of the reaction. Omission of the biotin-azide also
abolished retention of HDAC3 on streptavidin beads (lane 4),
showing that retention of HDAC3 on the streptavidin
beads requires the addition of biotin, and is not due to nonspe-
cific background binding of HDAC3 to the beads. A low, but
detectable level of cross-linking to HDAC2 was observed
(Figure 3A), but this cross-linking was not competed with 106,Elsevier Ltd All rights reserved
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the probe.
As a control, we synthesized a derivative of 1-BP lacking a
2-amino group in the HDAC inhibitor portion of the molecule,
which should not chelate zinc in the HDAC catalytic pocket
and hence should be far less active as an HDAC inhibitor (Butler
and Kozikowski, 2008). Indeed, this compound, 2-BP (Figure 1),
is at least 200-fold less active as an HDAC inhibitor, compared
with 1-BP (IC50 = 0.8 mM for 1-BP; IC50 > 180 mM for 2-BP, using
the HeLa nuclear extract as a source of HDACs). The parent
compound N1-phenyl-N7-phenylheptanediamide (termed 5b in
Herman et al., 2006) is a poor HDAC inhibitor (IC50 200 mM)
and also fails to activate FXN gene expression in the FRDA
lymphoblast cell line (Herman et al., 2006). When these two pho-
toaffinity reagents were compared for their ability to retain
HDAC3 on the streptavidin beads, 1-BP was found to be signif-
icantly more active in this regard than 2-BP (Figure 3B).
Figure 3. Identification of HDAC3 as the Target of 1-BP in a Nuclear
Extract
(A) Photoaffinity cross-linking of proteins in a nuclear extract from FRDA
lymphoblasts with 1-BP followed by addition of a biotin-azide by click chem-
istry, streptavidin binding, and Western blotting with antibodies to the indi-
cated HDACs. Lane 1, input (2% of the amount of total protein corresponding
to lanes 2–4 used for affinity capture); lane 2, proteins retained on streptavidin
beads; lane 3, same as lane 2 but with preincubation of a 20-fold excess of 106
prior to the addition of 1-BP to the extract; lane 4, no click chemistry control.
(B) Photoaffinity cross-linking and capture with 1-BP or 2-BP (each at 4 mM) as
above, and Western blotting with antibody to HDAC3. Lane 1, input (2% of
lanes 2–3); lane 2, proteins retained on streptavin beads after incubation
with 1-BP; lane 3, proteins retained on streptavin beads after incubation
with 2-BP, lacking a 2-amino group; lane 4, no click chemistry control.
(C) Competition with 106, TSA, and SAHA. Affinity capture with 1-BP (at 4 mM)
as in panel A, and Western blotting with antibody to HDAC3. Lane 1, input
(2% of lanes 2–6); lane 2, proteins retained on streptavidin beads; lane 3,
same as lane 2 but with preincubation with 106 (80 mM) for 1.5 hr prior to
the addition of 1-BP to the extract; lane 4, same as lane 3 but with preincuba-
tion with TSA (308 nM); lane 5, same as lane 3 but with preincubation with
SAHA (3 mM); lane 6, no click chemistry control. In lanes 3–5, the amounts of
competitor compounds correspond to 60 times the reported IC50 value for
each inhibitor.Chemistry & Biology 16, 980–9As additional controls for the specificity of HDAC3 capture by
1-BP, we performed preincubation experiments with either TSA
or SAHA (at 60 times their reported IC50 values) prior to the addi-
tion of 1-BP to the nuclear extract, and compared the ability of
these compounds to compete with 1-BP, to a similar excess of
106 (Figure 3C, lanes 3–5). Recall that neither TSA nor SAHA is
an activator of FXN transcription in cell culture (Herman et al.,
2006), and both of these compounds exhibit fast-on/fast-off
kinetics with class I HDACs, whereas 106 has slow-on/slow-off
kinetics with these enzymes (Chou et al., 2008). Clearly, 106 is
far more effective in competing with 1-BP for HDAC3 than is
either TSA or SAHA. Taken together, our results suggest that
HDAC3 is the primary cellular target of the pimelic diphenylamide
HDAC inhibitors, exemplified by 106 and related compounds
(Herman et al., 2006), and show that 106 forms a far more
stable complex with this enzyme than the hydroxamates TSA
and SAHA.
Role of Other Class I HDACs in FXN Gene Regulation
Although the results described above and previous studies
(Chou et al., 2008; Herman et al., 2006; Rai et al., 2008) strongly
suggest that HDAC3 is involved in FXN gene silencing, this
conclusion does not exclude a possible role for other HDACs
in FXN gene silencing in FRDA. We therefore chose to design
and synthesize an HDAC inhibitor that would have a different
enzyme specificity profile than 106, and to test such a compound
for effects on FXN transcription in FRDA cells. Recent studies
identified compounds with potent inhibition of HDAC1 and 2,
but with substantially reduced activity toward HDAC3 (Methot
et al., 2008). Although these compounds contained an aryl linker,
we hypothesized that appending a phenyl group at the 5-position
of the ‘‘right’’ hand ring of 106 would generate a compound with
specificity for HDAC1/2 over HDAC3 (compound 3, N1-(4-ami-
nobiphenyl-3-yl)-N7-phenylheptanediamide; Figure 1). IC50 and
Ki measurements for 3 with recombinant class I HDACs were
performed to determine the selectivity of such a pimelic acid
derivative (Figure 4 and Table S1). IC50 measurements for
HDACs 1 and 3 with compound 3 are shown in Figure 4A, and
enzyme progression curves in the presence of increasing
concentrations of 3 are shown in Figures 4B and 4D, along
with plots of Kobs versus inhibitor concentration (Figures 4C
and 4E). HDACi 3 has a 75-fold preference for HDAC1 over
HDAC3 comparing IC50 values (Figure 4a) and a 350-fold pref-
erence for HDAC1 over HDAC3 from Ki measurements (Figures
4C and 4E). HDACi 3 is also similarly active against recombinant
HDAC2 (data not shown). Thus, HDACi 3 and 106 are both active
inhibitors of HDAC1/2 (Chou et al., 2008), but addition of the
5-phenyl group has a pronounced deleterious effect on the
activity of 3 against HDAC3/NcoR2. Similar to 106, the kinetic
data for 3 and HDAC1 are best fit to a slow-on/slow-off inhibition
mechanism (Figure 4C and Chou et al., 2008).
Since 106 and 3 are both slow-on/slow-off inhibitors, we asked
whether HDACi 3 would cause prolonged acetylation of endog-
enous histones in the FRDA lymphoblast cell line, as we have
previously documented for 106 (Chou et al., 2008). Cells were
treated with 3 or 106, each at 10 mM, or with SAHA at 2 mM, for
24 hr in separate cultures, and the cells were then washed and
resuspended in fresh media lacking inhibitors. Aliquots of cells
were taken prior to washing and at time points ranging from89, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 983
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(A) IC50 determinations were performed as described elsewhere (Chou et al., 2008) with a 1 hr preincubation of HDAC1 or HDAC3/NcoR2 and inhibitor prior to
adding substrate. Enzyme progression curves for HDAC1 (B) or HDAC3/NcoR2 (D) in the presence of increasing concentrations of 3. In panel B, the curves, start-
ing at the top, represent the following final concentrations of inhibitor: no inhibitor, 0.5 mM, 1 mM, 2 mM, 4 mM, 8 mM, 12 mM, and 18 mM. In panel D, the curves
represent the following final concentrations of inhibitor: no inhibitor, 5 mM, 10 mM, 20 mM, 40 mM, 80 mM, 120 mM, and 180 mM. Plots of Kobs versus inhibitor
concentration for HDAC1 (C) and HDAC3/NcoR2 (E), as in (Chou et al., 2008). For HDAC1, the data are best fit to a slow-on/slow-off inhibition mechanism
involving a stable intermediate, while for HDAC3/NcoR2 a simple slow-on/slow-off mechanism provides the best fit to the data. Ki and R values (from the
least-squares fit to the data) are shown in the figure, while IC50 values are given in Table S1.0 to 7 hr after removal of the inhibitor. Levels of total histone H3
and acetylated histone H3 were monitored by Western blotting
(Figure 5A). Hyperacetylation of histone H3 was clearly seen
with each inhibitor in the cell cultures where inhibitors were
present, and at the zero time points, compared to the no inhibitor
control cultures (lanes marked ‘‘0’’). Hyperacetylation of histone
H3 due to the HDAC inhibitors 3 and 106 decreased only slightly
after inhibitor removal, and did not even fully return to basal levels
6–7 hr after the removal of the inhibitor. In contrast, histone H3
hyperacetylation due to SAHA disappeared rapidly after washing
the cells free of inhibitor. The level of acetylation returned to no-
inhibitor levels within 2 hr of removing SAHA from the medium, in
agreement with our previous study (Chou et al., 2008). Thus, both
3 and 106 cause prolonged histone acetylation in FRDA cells. We
also performed a titration experiment varying the exposure of
FRDA lymphoblasts to increasing concentrations of 3 or 106
and determined the levels of histone acetylation by Western blot-
ting. These two compounds were found to be comparably active
HDAC inhibitors in FRDA cells (Figure S2). To ensure that com-
pound 3 is not an inhibitor of class II HDACs, we monitored
tubulin acetylation after incubation of the FRDA lymphoblasts.
Tubulin acetylation is highly indicative of inhibition of class II
HDAC6 in cells (Wong et al., 2003). Neither 106 nor 3 caused
tubulin acetylation, whereas a potent class II HDAC inhibitor
(compound 4, see below) was highly active in inducing tubulin
acetylation (Figure S3).
We also prepared a photoaffinity version of HDACi 3 (3-BP)
and used this compound to identify cellular HDAC targets.984 Chemistry & Biology 16, 980–989, September 25, 2009 ª2009 E3-BP was incubated in the FRDA lymphoblast nuclear extract
and subjected to photo-cross-linking, and a biotin tag was
appended to the probe through Cu(I)-mediated click chemistry.
Streptavidin beads were again used for affinity capture, and
Western blotting with antibodies to the class I HDAC enzymes
HDAC1, 2, and 3, was used for target identification, with the
result that HDAC1 was identified as the likely cellular target of
this probe (Figure 5B). Much lower extents of recovery of HDACs
2 and 3 were found with this probe, compared with HDAC1.
Although the extent of recovery of HDAC1 with 3-BP is far less
than that observed for HDAC3 and 1-BP in the same nuclear
extract (Figure 3), the observed signal for HDAC1 is significant
over background (compared with a no click chemistry control,
lane 3) and reproducible in several experiments (data not
shown). Quantification of these experiments reveals that nine
times more HDAC1 than HDAC2 and five times more HDAC1
than HDAC3 are retained by 3-BP. We thus conclude that
HDAC1 is the primary class I HDAC target of 3-BP.
Having established that HDACi 3 is a potent HDAC inhibitor
in FRDA cells, we next asked whether this HDAC1-selective
compound would increase FXN mRNA in primary FRDA lympho-
cytes. Lymphocytes from FRDA patients were incubated for
48 hr with either 3 or 106, and FXN mRNA levels were quantified
by qRT-PCR, usingGAPDHmRNA as an internal control for each
determination. Patient lymphocytes have FXN mRNA levels of
10%–30% of those in lymphocytes from unaffected individuals
(Herman et al., 2006), and previous studies have shown that 106
increases FXN gene expression in patient lymphocytes (Railsevier Ltd All rights reserved
Chemistry & Biology
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FRDA Cells
(A) Histone acetylation in FRDA cells. FRDA
lymphoblasts were either untreated (DMSO
vehicle control, marked 0 at top) or treated with
HDACi 3 (top panels) or 106 (middle panels) at
10 mM, or with SAHA at 2 mM for 24 hr (lane marked
with ‘‘+’’ at top), washed to remove the inhibitors,
and the cells were suspended in fresh medium
lacking inhibitors. Aliquots of cells were harvested
at the indicated times (lanes marked 0–7 hr), and
protein extracts were prepared and subjected to
Western blotting with antibody to unacetylated
histone H3 as a loading control (indicated as Total
H3) or antibody to acetylated histone H3 (K9 +
K14; indicated as Ac-H3) for each of the inhibitors.
(B) Photoaffinity cross-linking of proteins in
a nuclear extract from FRDA lymphoblasts with
3-BP followed by addition of a biotin-azide by click
chemistry, streptavidin binding, and Western
blotting with antibodies to the indicated HDACs.
Lane 1, input (4% of the amount of total protein
corresponding to lanes 2–3 used for affinity
capture); lane 2, proteins retained on streptavidin
beads; lane 3, same as lane 2 but no click chem-
istry control (omission of the Cu(I) regent).
(C) Effects of HDACi 3 and 106 on FXN gene
expression in primary lymphocytes from FRDA
patients. Lymphocytes were isolated from donor
blood from a FRDA patient and were incubated
in culture media containing either 0.4% DMSO,
as a control, or 106 or the 5-phenyl compound 3,
each at the indicated concentrations in 0.4%
DMSO, for 48 hr prior to determination of mRNA
levels by qRT-PCR, using GAPDH mRNA as an
internal control. The y-axis denotes FXN mRNA
levels, normalized to GAPDH mRNA, relative to
the DMSO controls, set to 1.0. Each determination
was done in triplicate, and the SEM is shown. A
separate dose response experiment for 106 is
shown at the right.
(D) Effects of HDACi 3, 106 and SAHA on frataxin
protein expression in FRDA lymphoblasts. Cells
were incubated with each inhibitor (at 10 mM for
106 or 3 and at 2 mM for SAHA, in culture media
plus 0.1% DMSO or media plus DMSO as a control) for 48 hr prior to analysis by Western blotting for frataxin or GAPDH, as indicated. The X-ray films were
scanned and quantified, and the relative levels of frataxin protein, normalized to GAPDH protein, are shown at the bottom of the figure.et al., 2008). Although 106 is highly active in up-regulation of FXN
mRNA levels, 3 fails to reproducibly up-regulate FXN mRNA
levels in these cells (Figure 5C). We have observed small levels
of up-regulation of FXN mRNA in some experiments (up to
1.7 fold); however, this degree of up-regulation is never as large
as that observed for 106 (generally 3–4 fold) and is not consis-
tently observed (data not shown). To verify that HDACi 3 is
indeed active in cells, we monitored p21WAF1 mRNA levels in
HEK293 cells after treatment with SAHA or 3 and found that
both compounds increased the levels of this mRNA (data not
shown), as expected for a class I HDAC inhibitor (Gui et al.,
2004). We also examined frataxin protein levels by Western blot-
ting after incubation of FRDA lymphoblasts with HDACi 3, 106, or
SAHA, using GAPDH protein as a recovery standard (Figure 5D).
Quantification of these data reveals that only 106 had a positive
effect on frataxin protein levels, 3 was without significant effect,
and SAHA actually decreased frataxin levels in these cells.Chemistry & Biology 16, 980–We thus conclude that among the class I HDACs 1, 2, and 3,
increases in FXN gene expression and frataxin protein are only
observed with an inhibitor that preferentially targets HDAC3.
Class II HDACs and Sirtuin 1 in FXN Gene Silencing
To assess any potential contribution of class II HDACs to FXN
gene regulation in FRDA cells, we tested whether inhibitors of
these enzymes would have a positive effect on FXN mRNA
levels. On the basis of previous studies (Jones et al., 2008), we
synthesized 4 (tert-butyl 4-(6,6,6-trifluoro-5-oxohexanamido)-
phenylcarbamate; Figure 1), which we expected would have
a preference for class II HDACs over class I HDACs. IC50 deter-
minations with recombinant enzymes representing class I
(HDAC1) and class II (HDAC7) confirm this expectation: the
IC50 of 4 with HDAC7 is 4 mM, whereas the IC50 of this compound
with HDAC1 is 30 mM, showing a 7.5-fold preference for a class II
HDAC over a class I HDAC (Figure S4). Additionally, HDACi 4 is989, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 985
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(A) Class II HDAC inhibitor 4 causes tubulin acetylation in FRDA cells. FRDA lymphoblasts were incubated with the indicated concentrations of 4 or DMSO alone
(at 0.1%) for 24 hr in culture medium, prior to SDS-PAGE and Western blotting with anti-ac-tubulin antibody, or antibody to GAPDH, as a loading control.
(B) HDAC inhibitor 4 fails to activate FXN gene expression. FRDA lymphoblasts were incubated in culture media containing either 0.1% DMSO, as a control, or 4,
at the indicated concentrations in 0.1% DMSO, for 24 hr prior to determination of FXN mRNA levels by qRT-PCR, using GAPDH mRNA as an internal control. The
y-axis denotes FXNmRNA levels, normalized toGAPDHmRNA, relative to the DMSO control, set to 1.0. Each determination was done in triplicate, and the SEM is
shown.
(C) The Sirt1 inhibitor 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide fails to up-regulate FXN gene expression in primary lymphocytes from a FRDA
patient. Lymphocytes were incubated in culture media containing either 0.4% DMSO, as a control, or with the indicated concentrations of inhibitor in 0.4%
DMSO, for 48 hr prior to determination of mRNA levels by qRT-PCR, using GAPDH as an internal control, as in panel B.a potent inducer of tubulin acetylation in FRDA lymphoblast
cells (at 1 mM concentration in the culture medium for 24 hr;
Figure 6A). FRDA lymphoblasts were incubated with this
compound, but no positive effect was found on the levels of
FXN mRNA after treatment with concentrations up to 10 mM for
24 hr, suggesting that inhibition of class II HDACs has no effect
on FXN gene expression (Figure 6B). Similar experiments with
primary FRDA patient lymphocytes also failed to show up-regu-
lation of FXN transcription with HDACi 4 at concentrations up to
40 mM (Figure S5).
We also tested the Sirt1-specific inhibitor 6-chloro-2,3,4,9-
tetrahydro-1H-carbazole-1-carboxamide (Napper et al., 2005)
for effects on FXN transcription. This compound is a potent
Sirt1-specific inhibitor with a reported IC50 of 100 nM,
compared with IC50s of 20 and 50 mM for Sirt2 and Sirt3,
respectively. At concentrations ranging up to 10 mM, the
Sirt1 inhibitor had no effect on FXN mRNA levels in FRDA
patient lymphocytes (Figure 6C) or in either the FRDA lympho-
blast cell line or patient fibroblasts (data not shown), although
this compound has been shown to be cell permeable, and to
function as a Sirt1 inhibitor in several cell lines (Solomon et al.,
2006). Our results suggest that inhibition of Sirt1 does not986 Chemistry & Biology 16, 980–989, September 25, 2009 ª2009positively affect FXN gene expression, at least in FRDA
lymphocytes and fibroblasts.
DISCUSSION
Previous studies have shown that the pimelic diphenylamide 106
is a class I HDAC inhibitor with little or no activity against class II
HDACs (IC50s > 180 mM for class II enzymes) (Chou et al., 2008).
Among the class I HDACs, 106 shows a 10-fold preference for
HDAC3 over HDACs 1 and 2 (comparing Ki values, Table S1),
with only weak inhibitory activity against HDAC8. Our present
results pointing to HDAC3 as the target of 106 are in agreement
with these inhibition experiments with recombinant enzymes.
However, since 106 is a reasonable inhibitor of HDACs 1 and
2, it was somewhat surprising that our activity-profiling probe
1-BP failed to cross-link these enzymes to any appreciable
extent, either as recombinant enzymes (Figure 2A) or in a cell-
free extract (Figure 3A). Moreover, 1-BP is an effective inhibitor
of HDAC1 in vitro (IC50 = 0.57 mM), demonstrating that this
compound can indeed interact with HDAC1. We speculate that
the remarkable stability of the 106-HDAC3/NcoR2 complex
(Figure 2C) may account for this difference in cross-linkingElsevier Ltd All rights reserved
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demonstrated in dilution experiments and in cell-based histone
acetylation assays (Figure 5A and Chou et al., 2008). Histone
H3 acetylation in the FRDA lymphoblast cell line persists for
many hours after removal of 106 from the culture medium.
Although SAHA is also capable of inducing histone H3 acetyla-
tion in cells, removal of SAHA from the culture medium caused
a rapid loss in acetylated histones (Figure 5A), and SAHA fails
to activate the FXN gene in these cells (Chou et al., 2008; Herman
et al., 2006). Our previous kinetic study showed that SAHA is
a rapid-on/rapid-off inhibitor of class I HDACs (Chou et al.,
2008), and so we speculate that the stability of the 106-HDAC3
complex may account for the ability of this compound to act
as a positive regulator of FXN gene expression. Similarly, our
kinetic measurements indicated a difference in the inhibition
mechanism of 106 for HDACs 1 and 3, respectively. Although
106 inhibited both enzymes through slow-on/off mechanisms,
our data suggest that the 106/HDAC3/NcoR2 complex forms
a stable intermediate that is not observed for HDAC1. This differ-
ence may well explain why we fail to observe cross-linking of
1-BP to either recombinant HDAC1 or to HDAC1 in nuclear
extracts. Structural studies of these inhibitor/HDAC enzyme
complexes will be needed to elucidate the molecular basis for
this difference in stability and to explain why the pimelic dipheny-
lamides differ from hydroxamates in their inhibitory mechanisms
for class I HDACs.
Although the experiments shown in Figure 3 were performed
with a nuclear extract from human lymphoblasts, HDAC3 is
known to be present in the brain (see the Allen Brain Atlas at
www.brain-map.org and Broide et al., 2007), attesting to the
potential relevance of HDAC3 in neurological disease. Other
studies have clearly shown that the pimelic diphenylamides
function as HDAC inhibitors in the mouse brain, causing
increases in global histone acetylation in various brain regions
and reversing the gene expression changes associated with
FRDA and HD (Rai et al., 2008; Thomas et al., 2008). We are
currently exploring the ability of 1-BP to target HDAC3 in the
mouse brain. Our results with the 5-phenyl derivative, HDACi
3, suggest that only targeting HDAC3 can lead to up-regulation
of FXN mRNA levels in FRDA lymphoid cells. Similar to 106
and its mechanism of inhibition of HDAC3/NcoR2 (Chou et al.,
2008), inhibition of HDAC1 by 3 is also due to a slow-on/slow-
off mechanism, with a stable intermediate formed by the
enzyme-inhibitor complex (Figure 4). Although both 3 and 106
show prolonged histone H3 acetylation in cells (Figure 5A),
only 106 and other HDAC3-specific derivatives (such as 4b
and other derivatives; Herman et al., 2006) are effective inducers
of FXN gene expression (Figure 5C), resulting in increased levels
of frataxin protein (Figure 5D). Microarray studies comparing the
transcriptional profile of mouse embryonic stem cells and
HDAC1 knockout stem cells also fail to show an increase in
Fxn gene expression (Zupkovitz et al., 2006; see also http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5583), sug-
gesting that HDAC1 is not involved in regulation of the wild-
type Fxn gene. Similar knockout studies in FRDA cells or FRDA
mouse models may provide additional evidence for the role of
particular class I HDACs in FXN gene expression.
Although our current chemical approaches suggest that
HDAC3 plays an important role in gene silencing in FRDA, ourChemistry & Biology 16, 980–results do not distinguish between a direct or indirect role for
this enzyme. We showed that the pimelic diphenylamides cause
increases in histone acetylation at particular lysine residues at
the FXN locus in both FRDA lymphoid cells (Herman et al.,
2006) and in the brain of an FRDA mouse (Rai et al., 2008), clearly
pointing to the action of a histone acetyltransferase at the FXN
locus upon inhibition of an HDAC. Neither SAHA nor TSA had
such a positive effect on FXN histone acetylation (Herman
et al., 2006). Remarkably, the pattern of FXN histone H4 acetyla-
tion observed on treatment of FRDA cells with the related pimelic
diphenylamide 4b (which differs from 106 by a single methyl
group in the ‘‘left’’ phenyl ring) is similar to that observed after
genetic knockdown of HDAC3 (Hartman et al., 2005), where
H4K5 acetylation predominates (with the order of acetylated
residues as follows: H4K5 > K8 > K12 > K16). This pattern of
acetylation contrasts with the reported cellular effects of TSA,
where H4K16 is the most affected lysine residue (H4K16 > K12 >
K8 > K5) (Ren et al., 2005), and with the general effects of
SAHA at H3 and H4 lysine residues, at least on the p21WAF1
promoter (Gui et al., 2004). Taken together, these results are
supportive of a role of HDAC3 in causing increased histone
acetylation on the FXN gene. However, such acetylation
events at the FXN locus could be the consequence of inhibition
of another HDAC enzyme, through the indirect inhibition of
HDAC3. To assess this possibility, we have used chromatin
immunoprecipitation methods to examine occupancy of class I
HDACs on FRDA FXN alleles, but have failed to obtain
convincing evidence for such occupancy. This may be related
to either a transient association of HDACs with the FXN gene,
or to the indirect scenario suggested above. In another
approach, we attempted to knock down class I HDACs in cells
with various siRNA and shRNA approaches to see whether
such knockdown would cause FXN gene activation. Although
we are able to reduce class I HDAC mRNA levels using these
methods, no significant reduction in HDAC3 protein was
observed in lymphoid cells, and no effect on FXN mRNA was
observed. We are currently deriving a neuronal cell model for
FRDA based on human induced pluripotent stem (iPS) cells
(Ebert et al., 2008), in the hope that these molecular biology
approaches will be more amenable in neuronal cells. Notwith-
standing these caveats, our current chemical data clearly indi-
cate that inhibition of HDAC3 leads to FXN gene activation in
FRDA lymphoid cells, and suggests that this enzyme is a valid
therapeutic target for FRDA. It will be important to fully examine
the mechanisms responsible for FXN gene silencing in neuronal
models, such as iPS-derived cells.
SIGNIFICANCE
Numerous studies have pointed to HDAC inhibitors as
potential therapeutics for various neurological and neurode-
generative diseases, and clinical trials with several HDAC
inhibitors have been performed or are under way. However,
the HDAC inhibitors that have been tested to date are either
highly cytotoxic or have very low specificities for different
HDAC enzymes. In the course of studies on Friedreich’s
ataxia (FRDA), our laboratory identified a class of HDAC
inhibitors (pimelic diphenylamides) that reverse heterochro-
matin-mediated silencing of the frataxin (FXN) gene in this989, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 987
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cross the blood-brain barrier in mice, exhibit no acute or
chronic toxicity at potential therapeutic doses, and act as
HDAC inhibitors in the mouse brain. Importantly, our com-
pounds increase FXN mRNA levels in the brain and heart in
a mouse model for FRDA. We have now identified HDAC3
as the likely cellular target of the pimelic diphenylamides.
We find that a 5-phenyl derivative of our lead compound,
which preferentially inhibits HDACs 1 and 2, fails to fully acti-
vate FXN gene expression in FRDA cells. Although both the
HDAC3- and HDAC1/2-specific compounds share a similar
mechanism of inhibition of their target enzymes—namely,
a slow-on/slow-off binding of the inhibitor, generating
a stable inhibitor/HDAC enzyme complex—only HDAC3-
specific compounds increase FXN gene expression and
frataxin protein in cells. Additionally, a potent inhibitor of
class II HDACs and a Sirt1 inhibitor fail to show activation
of FXN gene expression in similar assays, again pointing to
HDAC3 as a target for therapeutic intervention in FRDA.
EXPERIMENTAL PROCEDURES
Cell Culture
The human Friedreich’s ataxia lymphoblast cell line GM15850 (Coriell Institute,
New Jersey) was grown in RPMI medium 1640 containing 10% FBS, 1%
HEPES, and 1% PMSF. Nuclear extracts were prepared by first adding cold
10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT, and
0.2 mM PMSF to washed cell pellets; after incubation on ice for 10 min, the
lysed cells were centrifuged at 3000 3 g for 15 min, and the soluble fractions
were removed. The pellet was resuspended in a 1:1 mixture of low salt buffer
(20 mM HEPES [pH 7.9], 25% glycerol, 20 mM KCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, and 0.2 mM PMSF) and high salt buffer (20 mM HEPES
[pH 7.9], 25% glycerol, 1.2 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, and 0.2 mM PMSF) and was subjected to homogenization, followed by
stirring at 4C for 30 min. The lysed nuclear pellet solution was centrifuged
at 14,000 3 g for 30 min at 4C to provide the nuclear fractions (supernatant)
and a membrane pellet. All fractions were stored at 80C until use.
Chemical Synthesis
HDAC inhibitors were synthesized as described elsewhere (Herman et al.,
2006), with modifications described in detail in the Supplemental Data. The
strategy for synthesis of trifunctional probes 1-BP, 2-BP, and 3-BP are pre-
sented in the schemes shown in Supplemental Data, along with detailed
procedures and analytical data for all compounds. The synthesis of the class
II inhibitor 4 is also described in Supplemental Data. Sirt1 inhibitor 6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide was purchased from Calbio-
chem (Sirt1 inhibitor III).
HDAC Inhibition Assays
Recombinant human HDAC1, HDAC 2, HDAC3/NcoR2, and HDAC8,
expressed in baculovirus, were purchased from BPS Bioscience (San Diego,
CA). The class II HDACs 4 and 5 were tagged with the Flag epitope from their
respective cDNAs (obtained from Addgene, Cambridge, MA), expressed in
HEK293t cells, and purified on Flag-M2 affinity resin (Sigma-Aldrich, MO), as
described elsewhere (Chou et al., 2008). The trifunctional probes, 106, and
other HDAC inhibitors were assayed with the BioMol AK500 kit to determine
IC50 values with recombinant HDACs or with a HeLa nuclear extract. Since
our previous studies indicated a slow on-rate for 106, these IC50 measure-
ments include a prolonged incubation time (1 hr) to ensure that the inhibitor-
enzyme complex came to equilibrium before initiation of the enzyme assay
(Chou et al., 2008). Samples were processed as described by BioMol and
read with a 96-well fluorescence plate reader. For class I HDACs, the synthetic
substrate acetyl-Lys(Ac)-AMC (from BioMol) was used, and deacetylated
lysine-AMC was released by trypsin treatment and free flourogenic 4-methyl-
coumarin-7-amide (MCA) was generated. The flourogenic MCA could then988 Chemistry & Biology 16, 980–989, September 25, 2009 ª2009 Ebe read with an excitation wavelength of 370 nm and emission wavelength
of 460 nm. Assays for class II HDACs were done using acetyl-Lys(trifluoroace-
tyl)-AMC (Lahm et al., 2007) under the same conditions. A semilogarithmic plot
of the data was analyzed with Kaleidagraph software (Synergy software) to
obtain the IC50 value. Ki values were determined from enzyme progression
curves, performed at various inhibitor concentrations, as described elsewhere
(Chou et al., 2008).
Photoaffinity Labeling of Recombinant HDAC Enzymes
Equal amounts (5 mg) of HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, and
HDAC5 were added to a 96-well plate, followed by addition of the trifunctional
probe to give a final concentration of 4 mM in 50 mL. After incubation on ice for
5 min, the solutions were photo-cross-linked with UV at 366 nm for 1-1.5 hr on
ice. Then click reagent (rhodamine-azide (RdN3), Tris[(1-benzyl-1-H-1,2,3-tri-
azol-4-yl)methyl]amine (ligand), Tris(2-carboxy-ethyl)phosphine hydrochloride
(TCEP), and CuSO4) was added to the solution to give final concentrations
of 86 mM RdN3, 53 mg/mL ligand, 0.29 mg/mL TCEP, and 1 mM CuSO4,
respectively, and was rotated at RT for 1.5 hr; 2–4 ml was taken from each reac-
tion for SDS-PAGE analysis. Fluorescent protein markers were a generous gift
of B. Cravatt and colleagues (Scripps). The gel was scanned with a Hitachi
FMBI011 instrument.
Streptavidin Bead Enrichment and Western Blotting
Three hundred microliters of nuclear extract (3.8 mg/mL protein) in 2100 ml PBS
was added to different wells in a 6-well plate, and in some experiments along
with competitor HDAC inhibitors, at the concentrations indicated in the figure
legends. In competition experiments, the competing HDAC inhibitor was
incubated with the extract for 2 hr at RT prior to addition of 1-BP; 240 ml trifunc-
tional probe was added to give a final concentration of 4 mM, and incubation
continued on ice for 5 min. Samples were then cross-linked with UV at
365 nm for one h on ice; 360 ml click reagent were added to the wells, as
described above, except using biotin-azide in place of rhodamine-azide, or
360 ml click reagent with no biotin-azide as a control, and the resulting solu-
tions were rotated at RT for 1 hr. One thousand microliters of PBS was added
to each well and the solution was kept at 20C overnight. The next day, the
solutions from each well were transferred to separate Eppendorf tubes and
centrifuged to precipitate proteins, which were then washed with cold meth-
anol (1 mL, twice), dried, resuspended in 1 ml of 0.2% SDS in PBS, and then
incubated with 0.8 ml of magnetic streptavidin beads (Invitrogen) for 2 hr.
(The supernatant was removed from the original bead solution, and the beads
were washed with PBS (1 mL, twice, prior to use). The supernatant was
removed, and the beads were washed with 0.2% SDS in PBS (1 mL, twice),
6 M urea (1 mL, twice), and PBS (1 mL, three times), and the resulting beads
were eluted with 60 ml 23 SDS loading buffer at 90, loaded onto three sepa-
rate SDS polyacrylamide gels, and subjected to Western blotting. Each
membrane was immunostained with antibodies to HDAC1, HDAC2, and
HDAC3 (all from Abcam), respectively, followed by anti-rabbit IgG-horseradish
peroxidase-conjugated secondary antibody (Cell Signaling, MA). Other anti-
bodies used in Western blotting experiments were anti-acetylated histone
H3 (Upstate Biotechnology), histone H3 (Abcam), acetylated tubulin (Abcam),
frataxin (Mitosciences), and GAPDH (Abcam). For quantification of Western
blots, the X-ray films, with exposures within the linear range of the film, were
scanned and converted into digital images, which were then analyzed with
ImageQuant software (Molecular Dynamics). After background correction,
the levels of the protein of interest were normalized to a reference protein as
a recovery or input standard.
Human Subjects, Primary Lymphocyte Isolation, and FXN mRNA
Determinations
All experiments were conducted with appropriate informed consent, under
a protocol approved by the Scripps Health Human Subjects Committee.
Primary lymphocytes were isolated from donor blood by ficoll density gradient
centrifugation (GE Healthcare), and mRNA determinations after incubation
with various HDAC inhibitors were performed as described elsewhere (Herman
et al., 2006).lsevier Ltd All rights reserved
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